10x Genomics (TXG) EBITDA Margin (2018 - 2026)

10x Genomics (TXG) posted EBITDA Margin of 11.3% for Q1 2026, up 3.99% sequentially from 11.77% in Q4 2025, and up 1409.0% YoY from 0.75% in Q1 2025.

10x Genomics (TXG) EBITDA Margin (2018 - 2026) Analysis & Trends

10x Genomics has reported EBITDA Margin for 9 years, with the latest figure at 11.3% in Q1 2026.

Quarterly EBITDA Margin rose 1409.0% year-over-year to 11.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.06% (up 2154.0% YoY) and the FY2025 annual result came in at 9.49%, up 2237.0% from the prior year.
EBITDA Margin advanced to 11.3% in Q1 2026 per TXG's latest filing, from 11.77% in the prior quarter.
Over five years, EBITDA Margin peaked at 17.42% in Q2 2025 and troughed at 61.7% in Q3 2023.
A 5-year average of 28.91% and a median of 30.0% in 2023 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2022 and 2025: EBITDA Margin plunged 4616 bps in 2022, then surged 4468 bps in 2025.
Over 5 years, EBITDA Margin stood at 14.78% in 2022, then slumped by 103 bps to 30.0% in 2023, then declined by 1 bps to 30.2% in 2024, then surged by 61 bps to 11.77% in 2025, then increased by 4 bps to 11.3% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 11.3%, 11.77%, and 21.64% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Veeva Systems	39.72 Bn	32.40 Bn	662.02 Mn	30.93%
2	BrightSpring Health Services	12.19 Bn	11.64 Bn	492.75 Mn	3.37%
3	Healthequity	8.79 Bn	8.52 Bn	256.31 Mn	29.03%
4	10x Genomics	7.31 Bn	6.76 Bn	112.50 Mn	-12.95%
5	Hinge Health	7.10 Bn	6.71 Bn	183.95 Mn	19.00%
6	MiniMed	5.66 Bn	5.36 Bn	480.00 Mn	-11.11%
7	Waystar Holding	4.76 Bn	4.56 Bn	221.99 Mn	23.79%
8	Doximity	4.46 Bn	3.77 Bn	132.93 Mn	21.48%
9	Heartflow	3.66 Bn	3.28 Bn	53.19 Mn	-27.93%
10	Privia Health	2.78 Bn	2.42 Bn	-	1.86%

Download Data